Vicuron Pharmaceuticals to Present at the Lazard Freres & Co. Healthcare Conference
29 Novembre 2004 - 1:30PM
PR Newswire (US)
Vicuron Pharmaceuticals to Present at the Lazard Freres & Co.
Healthcare Conference KING OF PRUSSIA, Pa., Nov. 29
/PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (Nasdaq and
Nuovo Mercato: MICU) today announced that George F. Horner III,
President and Chief Executive Officer, will present at the 1st
Annual Lazard Freres & Co. Healthcare Conference at 10:00 a.m.
Eastern Standard Time on Tuesday, November 30, 2004 at the Mandarin
Oriental Hotel in New York City, New York. To access the live audio
broadcast or the subsequent archived recording log on to
http://www.vicuron.com/ and click on the investor relations
section. Please connect to the website several minutes prior to the
start of the webcast to ensure adequate time for any software
download that may be necessary. The live broadcast will be archived
for 30 days. About Vicuron Vicuron Pharmaceuticals is a
biopharmaceutical company focused on discovering, developing,
manufacturing and commercializing vital medicine for seriously ill
patients. In May 2004, Vicuron received an approvable letter from
the FDA for its lead product anidulafungin for the treatment of
esophageal candidiasis. The company's other lead product,
dalbavancin, a novel intravenous antibiotic for the treatment of
serious Gram-positive infections, has completed Phase 3 clinical
trials. The company's versatile research engine integrates
industry-leading expertise in functional genomics, natural products
discovery, mechanism-based drug design and combinatorial and
medicinal chemistry. These approaches are yielding promising novel
and next-generation compounds, many of which are in the later
stages of preclinical development. In addition, the company has
research and development collaborations with leading pharmaceutical
companies, such as Pfizer and Novartis. Forward-Looking Statements
This news release contains forward-looking statements that predict
or describe future events or trends. The matters described in these
forward- looking statements are subject to known and unknown risks,
uncertainties and other unpredictable factors, many of which are
beyond Vicuron's control. Vicuron faces many risks that could cause
its actual performance to differ materially from the results
predicted by its forward-looking statements, including the
possibilities that clinical trials and the results thereof might be
delayed, or unsuccessful, that the timing of the filing of any new
drug application or any amendment to a new drug application might
be delayed, that clinical trials might indicate that a product
candidate is unsafe or ineffective, that the FDA might require
additional information to be submitted and additional actions to be
taken before it will make any decision, that any filed new drug
application may not be approved by the FDA, that ongoing
proprietary and collaborative research might not occur or yield
useful results, that the pipeline may not yield a new clinical
candidate or a commercial product, that a third party may not be
willing to license our product candidates on terms acceptable to us
or at all, that competitors might develop superior substitutes for
Vicuron's products or market these competitive products more
effectively, that a sales force may not be developed as
contemplated and that one or more of Vicuron's product candidates
may not be commercialized successfully. The reports that Vicuron
files with the U.S. Securities and Exchange Commission contain a
fuller description of these and many other risks to which Vicuron
is subject. Because of those risks, Vicuron's actual results,
performance or achievements may differ materially from the results,
performance or achievements contemplated by its forward- looking
statement. The information set forth in this news release
represents management's current expectations and intentions.
Vicuron assumes no responsibility to issue updates to the
forward-looking matters discussed in this news release. DATASOURCE:
Vicuron Pharmaceuticals Inc. CONTACT: Dov A. Goldstein, M.D. of
Vicuron Pharmaceuticals Inc., +1-610-205-2312, or ; or Hala Mirza
of WeissComm Partners, +1-212-204-2080, or , or Aline Schimmel of
Burns McClellan Inc., +1-212-213-0006, or , both for Vicuron
Pharmaceuticals Inc. Web site: http://www.vicuron.com/
Copyright